Abstract

THERAPEUTIC EFFICACY OF ABRAXANE

G. Vaishnavi*, S. L. Manjusha, N. Mohana Sree and sd. Abdul Jabbar Basha

.

Abstract

This article is related to therapeutic efficiency of ABRAXANE. ABRAXANE is a antitumor agent which is having hydrophobic nature, to overcome this property lipid based solvents are added as vehicles. ABRAXANE is the albumin-bounded 130° nanometer particle formulation paclitaxel. Since the standard dose of paclitaxel has lower incidences of toxicities, it is used in different types of malignant tumors. In the phase-III clinical trials nab – paclitaxel demonstrated higher response rates, better safety and side effects profile. Compared to conventional paclitaxel and improved survival in patients receiving it as second line therapy. ABRAXANE as superior efficacy to eliminate CSC’s in comparison with TAXOLS. The pharmacokinetic data of 260mg /m2 of ABRAXANE administered over 30 minutes was compared with pharmacokinetic data of 175mg/m2 of paclitaxel injection over 3 hours. The volume of distribution of ABRAXANE was higher (53%) than paclitaxel and the volume of clearance of ABRAXANE was found to be larger (43%) than paclitaxel injection.

Keywords: Abraxane, Paclitaxel, Tumor, Efficacy.